Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
3.790
-0.100 (-2.57%)
Jul 23, 2025, 1:20 PM - Market open
Lexeo Therapeutics Employees
Lexeo Therapeutics had 72 employees as of December 31, 2024. The number of employees increased by 14 or 24.14% compared to the previous year.
Employees
72
Change (1Y)
14
Growth (1Y)
24.14%
Revenue / Employee
n/a
Profits / Employee
-$1,518,153
Market Cap
204.65M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 72 | 14 | 24.14% |
Dec 31, 2023 | 58 | 34 | 141.67% |
Dec 31, 2021 | 24 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
LXEO News
- 16 days ago - Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia - GlobeNewsWire
- 4 weeks ago - Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics - GlobeNewsWire
- 2 months ago - Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases - GlobeNewsWire
- 2 months ago - Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights - GlobeNewsWire
- 2 months ago - Lexeo: Alignment Gained With FDA Brings Further LX2006 Program Advancement - Seeking Alpha
- 2 months ago - Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting - GlobeNewsWire
- 3 months ago - Gene Therapy For Fatal Rare Disease-Associated Heart Condition - Lexeo Therapeutics Candidate Shows Improvements In Trials - Benzinga
- 3 months ago - Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study - GlobeNewsWire